undamentalytics Newsletter
Sign in

Foghorn Therapeutics Inc. revenue

Foghorn Therapeutics Inc.'s revenue was $30.9m in fiscal 2025, up 36.8% on the year before. Since fiscal 2020 ($430,000) it has grown at a compound 135.1% a year. Over the last twelve months it was $36.7m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue011934233137
Growth on the year before—+206.7%+>999%+77.6%−33.8%+36.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Foghorn Therapeutics Inc. $36.7m 52.0% 19.1%
Nanobiotix S.a. $36.9m 678.4% —
Zymeworks Inc. $37.1m -69.8% -56.4%
Cue Biopharma, Inc. $37.7m 354.4% 176.2%
C4 Therapeutics, Inc. $35.0m 2.3% 29.8%
Bioharvest Sciences Inc. $34.5m 37.0% —

Compare with peers

Head to head: FHTX vs NBTXFHTX vs ZYMECUE vs FHTXCCCC vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Foghorn Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Foghorn Therapeutics Inc.